CREON Dosing for Chronic Pancreatitis or Pancreatectomy

CREON has specific dosing for patients with chronic pancreatitis (CP) or pancreatectomy*

(36,000 lipase unit)
capsules with every meal

2

(36,000 lipase unit)
capsule with snacks

1

Meals for illustrative purposes only

Capsules shown are not actual size and do not represent the exact color shade

*CP/Pancreatectomy Study: Patient received either placebo or 72,000 units of lipase per main meal (3 main meals) and 36,000 units per snack (2 snacks) while consuming 100 grams of fat per day1,2

Dosing Considerations

  • Usually, half of the prescribed CREON dose for an individualized full meal should be given with each snack.
  • For all patients the CREON dosage should be individualized and adjusted based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet.
Use the CREON® (pancrelipase) Treatment Tracker to help educate patients about their therapy

Encourage patients to track treatment and share the results with you

Download
Treatment Tracker
CREON On Course makes it easy for patients to receive benefits for CREON

Help patients get nutritional, financial, and educational resources

Learn More
Request patient starter kits, product samples, and more

Request patient starter kits, product samples, and more

Contact a Rep

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. References:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.
  3. Whitcomb DC, Lehman GA, Vasileva G, et al. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: a double-blind randomized trial. Am J Gastroenterol. 2010;105(10):2276-2286.

back to top #tbd